For instance, an antagonist of gastrin-releasing peptide receptor43 and prostate-specific membrane antigen conjugate44 for FGS in prostate cancer were shown to provide TBRs (muscle) ranging from ∼7.5 to 25. This evidence concerns the gene FOLH1 and prostate cancer.